Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts LCTX Hot Sheet
Join SI Premium – FREE
Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $4.57 million.
For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
- Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c
- Nebius soars on second quarter revenue beat
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
